Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2
Study to Predict Your Therapeutic Response (I-SPY 2 Trial)
Sponsor: QuantumLeap Healthcare Collaborative QLHC
Enrolling: Male and Female Patients
IRB Number: AAAR1925
U.S. Govt. ID: NCT01042379
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The primary purpose of this trial is to determine whether adding new drugs to the standard initial cancer treatments for breast cancer increases the probability there there will be no residual disease (cancer cells left after many attempts to remove the cancer), compared to the initial cancer treatment alone. The intervention includes different drugs to determine which study drugs might result in better outcomes than standard treatment.
Investigator
Meghna Trivedi, MD
Do You Qualify?
Are you 18 years or older? Yes No
Have you been diagnosed with breast cancer? Yes No
Have you had chemotherapy already? Yes No
Are you not pregnant and are willing to not become pregnant while on this trial? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162